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Induction of Human T-cell and 
Cytokine Responses Following 
Vaccination with a Novel Influenza 
Vaccine
David A. G. Skibinski1,2, Leigh Ann Jones1, Yuan O. Zhu3, Lin Wu Xue1, Bijin Au  1, 
Bernett Lee4, Ahmad Nazri Mohamed Naim3, Audrey Lee1, Nivashini Kaliaperumal1, 
Jenny G. H. Low5,6, Lawrence S. Lee7,8, Michael Poidinger4, Philippe Saudan9, 
Martin Bachmann10, Eng Eong Ooi11, Brendon J. Hanson12, Veronica Novotny-Diermayr13, 
Alex Matter13, Anna-Marie Fairhurst  4, Martin L. Hibberd3 & John E. Connolly1,2,14
Cell mediated immunity plays a vital role in defense against influenza infection in humans. Less is 
known about the role of vaccine-induced cell mediated immunity and the cytokine responses elicited. 
We measured CD4+ and CD8+ T-cell reactivity in human subjects following vaccination with licensed 
trivalent influenza vaccine and a novel virus-like particle based vaccine. We detected influenza-specific 
CD4+ T-cell responses following vaccination with the licensed trivalent influenza vaccine and found that 
these correlated with antibody measurements. Administration of the novel virus-like particle based 
vaccine elicited influenza-specific CD4+ and CD8+ T-cell responses and the induction of the cytokines 
IFN-γ, IL-17A, IL17F, IL-5, IL-13, IL-9, IL-10 and IL-21. Pre-existing cytokine responses influenced 
the profile of the cytokine response elicited by vaccination. In a subset of individuals the VLP vaccine 
changed pre-vaccination production of type 2 cytokines such as IL-5 and IL-13 to a post-vaccination 
type 1 cytokine signature characterized by IFN-γ. A transcriptional signature to vaccination was found 
to correlate with antibody titer, IFN-γ production by T-cells and expression of a putative RNA helicase, 
DDX17, on the surface of immune cells.
The most established correlate of protection against influenza infection are antibodies targeting influenza virus 
envelope glycoprotein haemagglutinin (HA)1. However numerous clinical studies have demonstrated an impor-
tant role for T-cells in driving protection. The number of influenza-specific interferon-γ (IFN-γ) producing CD4+ 
T-cells negatively correlate with the development of disease in antibody-naive healthy volunteers following influ-
enza challenge2. Another study reported that the frequency of influenza-specific IFN-γ producing CD8+ T-cells 
positively correlated with less severe illness in a healthy adults following natural3.
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Immune responses to influenza vaccination are characterized by antibody levels with licensure criteria 
dependent on haemagglutinin inhibition (HAI) titers4. However, currently available vaccine regimens, fail to 
confer protection to all individuals, particularly elderly subjects5. The current Trivalent Influenza Vaccine (TIV) 
is poor at eliciting CD4+ T-cell6–15 or CD8+ T-cell11,16 responses after vaccination, and much recent focus has been 
on finding an association between T-cell responses and influenza specific antibody responses17–20. Nayak et al.19 
found that, in individuals vaccinated with the monovalent inactivated pandemic 2009 H1N1 vaccine, the expan-
sion of influenza- CD4+ T-cells correlated with neutralizing antibody titers. Research with adjuvanted influenza 
vaccine, found that the presence of CD4+ T-cells specific for the vaccine were predictive of long term maintenance 
of protective antibody titers18. A follow up study revealed that influenza-specific ICOS+ IL-21+ CD4+ T-cells were 
associated with a rise in functional antibodies20. Together this work has made important contributions towards 
understanding the input of T-cells in driving humoral immunity following vaccination. However, less is known 
about the full range of T-cell responses that are induced across different T-cell subsets, and how pre-existing 
immunity can shape these responses post-vaccination.
Here, we utilized flow cytometry and multiplex-immunoassays to fully characterize T-cell responses and 
the spectrum of cytokine responses in healthy adults both before and after vaccination with TIV and a novel 
virus-like particle (VLP) based vaccine. We detected pre-existing influenza-specific responses in these individ-
uals. Vaccination with both TIV and VLP enhanced the magnitude of T-cell responses without fundamentally 
altering the profile of cytokines produced. However, with the VLP vaccine, we identified a subset of individuals 
whose response shifted from a pre-existing T helper type 2 (Th2) cytokine profile bias towards a T helper type 1 
(Th1) cytokine profile.
Finally, using whole blood transcriptional analysis, we determined that a putative RNA helicase, DDX17, is 
down regulated following vaccination with the virus-like particle based vaccine, and identified a transcriptional 
signature to vaccination which correlates with antibody titer, IFN-γ cytokine response and expression of DDX17 
on the surface of circulating immune cells.
Results
CD4+ T-cell proliferation correlates with neutralizing antibody responses to trivalent influenza 
vaccination. Ten healthy adults aged 21–56 years received two doses of Trivalent Influenza Vaccine (TIV; A/
California/7/2009 (H1N1), A/Perth/16/2009 (H3N2) and B/Brisbane/60/2008) twenty-one days apart. Geometric 
mean HAI titers to H1N1 increased from 35 before vaccination to 368 and 422 after one and two doses respec-
tively (Fig. 1A). Seroconversion was observed in 9 subjects (90%) after one dose and in all subjects (100%) after 
two doses of the vaccine. Similar results were determined using the microneutralization (MN) assay, with a posi-
tive correlation (rs = 0.40, p = 0.03) between the two assays (Fig. 1A,B).
To analyze the influenza specific T-cell responses to TIV vaccination, CFSE-labelled peripheral blood mono-
nuclear cells (PBMCs) from vaccinated individuals were stimulated in vitro with the vaccine or with peptide pools 
specific for the HA and NP/MP1 influenza proteins. CD4+ T-cell proliferation was detected using CFSE dilution 
(Supplementary Fig. S1). There was a significant increase in proliferation following a single dose with either TIV 
or HA stimulation (Fig. 1C; Supplementary Table S1). HA-specific CD4 proliferative responses remained high fol-
lowing the second dose of vaccine. Proliferation of NP/MP1 specific CD4+ T-cells pre- and post-vaccination was 
equivalent despite NP and MP1 proteins being detectable in the vaccine using Mass Spectroscopy (Supplementary 
Table S1). There was no detection of influenza-specific CD8+ T-cell or B cell proliferation to TIV vaccination 
(Supplementary Fig. S2A and B). Stimulation with PMA and ionomycin did not increase response post vaccina-
tion (Supplementary Fig. S2C). After eight days in vitro stimulation proliferating TIV-specific CD4+ T-cells were 
predominantly positive for the T follicular helper (Tfh) markers ICOS and PD-1 yet, as previously described20, 
these influenza-specific T-cells were negative for CXCR5 (Supplementary Fig. S3). It is important to consider that 
the in vitro stimulation step has the potential to change the expression of those markers, and therefore it may not 
reflect their expression on these cells in blood.
As previously reported19 we found a correlation between the change in the TIV-specific CD4+ T-cell response 
and the MN titer (r2 = 0.48, p = 0.02) after one dose of the vaccine (Fig. 1D).
The pre-existing influenza-specific cytokine profile is retained following TIV vaccination. To 
examine the quality of the cytokine response observed following TIV vaccination, TIV- and peptide- stimulated 
PBMC cultures were assayed for cytokine levels at day 8 post stimulation (Supplementary Tables S2 and S3). Of 
the 15 cytokines and chemokines tested only TIV-specific IL-10 levels (P < 0.01) were greater following vaccina-
tion (Supplementary Fig. S4). We found no correlation between cytokine response and MN titer (data not shown). 
Ideally, to look at the quality of the response, as opposed to the magnitude, we should look at the distribution 
of cytokine responses in relation to each other. However, comparing different cytokines is hampered by the fact 
that their relative levels are orders of magnitude apart. In an attempt to investigate this, we normalized the data 
by defining a positive response for each cytokine in each individual subject as being greater than two-standard 
deviations above the background for that analyte. As expected we found that positive cytokine responses were 
equally distributed following stimulation with PMA and ionomycin (Fig. 2A). Although, as described above, 
cytokine levels from TIV or HA stimulated PBMCs were largely unchanged there is a trend towards more individ-
ual positive responses following vaccination (Fig. 2B). The proportional distribution of these individual cytokine 
responses did not change following vaccination.
Vaccination with gH1-Qbeta elicits influenza-specific CD4+ and CD8+ T-cell responses. The 
gH1-Qbeta vaccine is a novel pandemic-influenza vaccine produced by covalently linking the globular head 
domain of haemagglutinin (gH1) from A/California/07/09 produced in E. coli to VLPs from the bacteriophage 
Qbeta21. The vaccine has been evaluated in a Phase I clinical study where, following the regimen for the above TIV 
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study, 84 healthy adults aged 21–64 years received two doses of the vaccine twenty-one days apart22. Subjects were 
randomized to receive alum-adjuvanted (n = 43) and non-adjuvanted vaccine (n = 41) with the latter formulation 
reaching the primary immunogenicity endpoint of 60% seroconversion (62.2% and 70.3% of individuals sero-
converting after one and two doses of the respectively). The alum-adjuvanted formulation demonstrated inferior 
performance, failing its primary endpoint (seroconversion in only 25.5% and 51.2% of individuals after one and 
two doses respectively; Fig. 3A)22.
Figure 1. CD4+ T-cell responses predict neutralizing antibody responses to trivalent influenza vaccination. 
(A) HAI antibody responses (left) and MN antibody responses (right) against A/California/07/2009 following 
Fluarix vaccination. One way ANOVA. ****P < 0.0001, ***P < 0.001, Tukey’s test. ns, not significant. (B) 
Correlation between HAI and MN titers after one dose of vaccine. Spearman rank correlation test. n = 10, data 
points overlap. (C) Proliferating CD4+ T-cells in cultures of PBMCs isolated from subjects vaccinated with TIV. 
PBMCs were stimulated with the TIV vaccine and peptide pools specific for A/California/7/2009 HA, MP1 and 
NP proteins. Friedman test. *P < 0.05, Dunn’s test. ns, not significant. (D) Correlation between MN titer (Post 1)  
and the change in TIV-specific CD4+ T-cell response (post 1 response – baseline response). Spearman rank 
correlation test. Labels “Pre”, “Post1” and “Post2”, refer to Day 0, Day 21 and Day 42 post primary vaccination 
respectively.
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In an identical manner to the TIV challenge described above, CFSE-labelled PBMCs from the gH1-Qbeta 
vaccinated individuals were stimulated in vitro with peptide pools specific for gH1 and Qbeta. The gH1-Qbeta 
vaccine was found to elicit gH1-specific CD4+ and CD8+ T-cell responses regardless of adjuvant (Fig. 3B). Using 
the same gH1-specific peptide pool similar gH1-specific increases were not observed following TIV vaccination 
(Supplementary Fig. S5). As expected, there were no differences in PMA/ionomycin induced T cell activation 
pre- and post-vaccination (Supplementary Fig. S6).
Qbeta-specific challenge also resulted in increased CD4+ and CD8+ T-cell proliferation (Fig. 3C), and when 
directly compared, this increase was determined to be higher for the adjuvanted versus unadjuvanted vaccine 
following both one and two doses (p = 0.014 and p = 0.022 respectively). This enhancement of responses to Qbeta 
(the non-influenza specific component of the vaccine) could reflect the potential requirement of the adjuvant 
to elicit responses to antigens for which there is no pre-existing immunity. Contrary to our findings with TIV 
vaccine, we found no significant correlation between CD4+ or CD8+ T-cell proliferation and MN titers for either 
non-adjuvanted or adjuvanted groups (data not shown).
Ex-vivo analysis of PBMCs without simulation identified post vaccination contraction of the peripheral cen-
tral memory pool of T-cells and an expansion of the effector memory pool (Figs 3D and S7).
Vaccination with gH1-Qbeta elicits a poly-functional influenza-specific cytokine response. We 
then assessed the production of cytokines following exposure to gH1 peptides in gH1-Qbeta vaccinated indi-
viduals. We determined increases in IFN-γ, IL17A, IL-17F and IL-9 in both adjuvanted and non-adjuvanted 
groups (Table 1). Furthermore, the IFN-γ levels were found to correlate with CD4+ T-cell proliferation 
Figure 2. Quality of the pre-existing influenza-specific cytokine profile remains unchanged following TIV 
vaccination. (A,B) Distribution of positive cytokine responses from subjects before and after vaccination with 
trivalent influenza vaccine (n = 10). PBMCs were cultured with (A) PMA and ionomycin, and (B) the TIV 
vaccine and peptide pools specific for A/California/7/2009 HA, MP1 and NP proteins. Levels of the indicated 
cytokines were measured in the cell culture supernatants after eight days incubation. The size of the charts is 
proportional to the magnitude of the response (number of positive responses in all subjects for that visit is 
indicated for each chart; maximum of 150). Labels “Pre”, “Post1” and “Post2”, refer to Day 0, Day 21 and Day 42 
post primary vaccination respectively.
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Figure 3. Vaccination with gH1-Qbeta vaccine elicits gH1-specific CD4+ T-cell proliferation. (A) HAI 
antibody responses against A/California/07/2009 following gH1-Qbeta vaccination. One way ANOVA. 
****P < 0.0001, Tukey’s test. ns, not significant. (B) Proliferating gH1-specific CD4+ (left) and CD8+ (right) 
T-cells in cultures of PBMCs isolated from subjects vaccinated with non-adjuvanted and adjuvanted gH1-Qbeta 
vaccine. Friedman test. ****P < 0.0001, Dunn’s test. ns, not significant. (C) Proliferating Qbeta-specific CD4+ 
(left) and CD8+ (right) T-cells in cultures of PBMCs isolated from subjects vaccinated with non-adjuvanted 
and adjuvanted gH1-Qbeta vaccine. Friedman test. ****P < 0.0001, **P < 0.01 Dunn’s test. ns, not significant. 
(D) T-cell subsets present in PBMCs of cohort vaccinated with non-adjuvanted gH1-Qbeta. Wilcoxon test. 
****P < 0.0001, ***P < 0.001, **P < 0.01 Dunn’s test. ns, not significant. Labels “Pre”, “Post1” and “Post2”, refer 
to Day 0, Day 21 and Day 42 post primary vaccination respectively.
www.nature.com/scientificreports/
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(Supplementary Fig. S8). In the adjuvanted group, gH1-specific increases in IL-5, IL-13 and IL-21 were also 
observed. We observed similar increases in gH1-specific responses in the TIV however, these were not significant 
(Supplementary Table S4).
Exposure to the Qbeta-peptides resulted in increases in IFN-γ, IL-17A, IL-17F and IL-5 by PBMCs from 
individuals receiving adjuvanted or non-adjuvanted Qbeta vaccines. The adjuvanted vaccine also induced 
Qbeta-specific increases in IL-13, IL-9 and IL-21 (Supplementary Table S5).
Vaccination with gH1-Qbeta drives an influenza-specific IFN-γ response in a subset of individuals. 
Similar to our study in the TIV cohort, in order to look at the quality of response, we normalized the cytokine data 
in an attempt to look at their relative distributions. Again, cytokine responses were equally distributed, follow-
ing stimulation with PMA and ionomycin (Supplementary Fig. S9). Also, the distribution of individual positive 
cytokine responses relative to other cytokines did not fundamentally change following gH1-Qbeta vaccination 
(Fig. 4A,B).
The large increase in IFN-γ levels observed with the adjuvanted gH1-Qbeta vaccine is also reflected in the 
number of individual positive IFN-γ responses compared to other cytokines with a trend to more individual 
positive IFN-γ responses for both gH1- and Qbeta-specific responses (Fig. 4A,C).
A comparison of T helper type 2 (Th2) cytokines (IL-5 and IL-13) to the T helper type 1 (Th1) cytokine IFN- γ 
reveal a clear skewing following vaccination with the ratio of IFN-γ to IL-13 and IL-5 increasing following vacci-
nation (Supplementary Fig. S10). This capacity of the gH1-Qbeta vaccine to preferentially elicit IFN-γ is seen in a 
subset of individuals whose pre-existing influenza-specific cytokine responses were characterized by the T helper 
type 2 (Th2) cytokines IL-5 and IL-13 (Fig. 5).
DDX17, a putative RNA helicase, is down-regulated following vaccination. We next examined 
the whole blood transcriptome of individuals receiving the gH1-Qbeta vaccination. We analyzed the adjuvanted 
and non-adjuvanted groups and therefore identified two lists of differentially expressed genes (DEGs) 42 days 
post vaccination, relative to expression at day 0 (Fig. 6A). When DEGs were filtered based on a fold change 
threshold of 2, DDX17, a putative RNA helicase, was identified as being significantly down regulated following 
vaccination in adjuvanted and non-adjuvanted groups (Fig. 6A,B). Flow cytometry analysis on PBMCs revealed 
that DDX17 protein expression was reduced on a number of leukocyte subsets including pDCs, intermediate and 
non-classical monocytes, B-cells, CD4+ T-cells, CD8+ T-cells and NK cells (Fig. 6C). DDX17 expression was also 
reduced in T-cell subpopulations including central and effector memory CD4+ T-cells following vaccination 
(Supplementary Fig. S11).
Cytokine/Chemokine
Non-adjuvanted Adjuvanted
Day 0 Day 21 Day 42 Day 0 Day 21 Day 42
Proinflammatory
   IFN-γ 34.18 137.38 138.55 37.76 257.89 211.80
   IL-2 4.91 0.80 0.71 4.73 0.01 0.01
   TNF-β (LTα) 0.01 0.01 0.01 0.01 0.01 0.01
   IL-6 4996.66 15438.32 4752.26 5260.17 15465.00 4911.00
   TNF-α 161.17 165.73 155.83 200.76 212.66 190.88
   MIP-3α (CCL20) 143.70 174.80 84.49 141.99 140.32 100.57
Th2
   IL-4 0.01 0.01 0.01 0.01 0.01 0.01
   IL-5 1.63 5.79 5.58 1.59 5.28 5.39
   IL-13 34.41 73.18 58.48 31.72 90.44 68.04
Th17
   IL-17A 8.42 30.64 33.24 8.76 20.88 13.25
   IL-17F 0.11 0.40 0.25 0.08 0.40 0.28
Th9
   IL-9 0.54 2.05 2.48 0.07 3.25 5.39
   Th22
   IL-22 0.01 0.01 0.01 0.01 0.01 0.01
Treg
   IL-10 17.95 23.09 17.78 16.28 23.27 19.83
Tfh
   IL-21 0.01 0.01 0.01 0.01 0.61 0.47
Table 1. gH1-specific cytokine responses following vaccination with gH1-Qbeta. Data are median gH1-specific 
cytokine responses, pg/ml, measured by 15-plex assay in supernatants from PBMC cultures that were stimulated 
with peptide libraries specific for gH1 for 8 days. Boldface and underlined text represents values for which there 
is statistical evidence of higher median values compared with median values at baseline. IL-2 in the adjuvanted 
group possessed statistically lower median values compared with median values at baseline. In the non-adjuvanted 
group between one and two doses of vaccine statistically lower median values were observed for MIP-3α.
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A transcriptional signature to vaccination correlates with DDX17 expression HAI titer and the 
influenza-specific IFN-γ T-cell response. We then studied the regulation of groups of genes via a weighted 
correlation network analysis (WGCNA) to identify clusters of genes whose change in expression was associated 
with each other. These clusters of genes were assessed for correlations to HAI titer, T-cell responses and DDX17 
expression and compared to previously identified Blood Transcriptional Modules (BTMs)23 to identify biolog-
ical functions associated with the gene clusters (Fig. 6D). Multiple gene clusters were positively correlated with 
HAI titer, including a module (indicated in brown) enriched for genes related to IL-3 signaling, protein export, 
vitamin B biosynthesis and CoA synthesis. Notably, a specific cluster, indicated in pink, which is enriched in 
CORO1A-DEF6 network genes, demonstrated reduced activity following vaccination and correlated positively 
with DDX17 expression, and negatively with HAI titer and influenza-specific IFN-γ cytokine response.
Figure 4. Vaccination with gH1-Qbeta elicits a poly-functional influenza-specific cytokine response. 
Distribution of positive cytokine responses from subjects vaccinated with (A,C) non-adjuvanted gH1-Qbeta 
(n = 37), (A,C) adjuvanted gH1-Qbeta (n = 43) and (B) trivalent influenza vaccine (n = 10). PBMCs were 
cultured with (A,B) peptide pools covering the gH1 antigen sequence, and (C) peptide pools covering the 
Qbeta sequence. Levels of the indicated cytokines were measured in the cell culture supernatants after eight 
days incubation. The size of the charts is proportional to the magnitude of the response (number of positive 
responses in all subjects for that visit is indicated for each chart; maximum of 150 for TIV, 555 for non-
adjuvanted gH1-Qbeta, and 645 for adjuvanted gH1-Qbeta). Labels “Pre”, “Post1” and “Post2”, refer to Day 0, 
Day 21 and Day 42 post primary vaccination respectively.
www.nature.com/scientificreports/
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Discussion
The 2009 H1N1 pandemic highlighted the global threat posed by influenza A viruses and has sparked a flurry 
of interest in the development of vaccines to prepare for future, and potentially more serious pandemics24–30. 
Effective influenza vaccination is currently assessed by anti-influenza antibody levels due to the accepted and 
established importance of humoral immunity on protection4. Studies have shown that cellular responses play an 
important role in protection, with associations drawn between pre-existing IFN-γ -producing influenza-specific 
CD4+ and CD8+ T-cells and less severe disease2,3. Since the current TIV vaccine is inefficient at driving T cell acti-
vation6–12,14–16,18, a need exists for strategies which can engage both humoral and cell mediated immunity. Herein, 
we present a novel VLP vaccine able to induce seroconversion and elicit influenza-specific T-cell responses.
In pre-clinical studies we have demonstrated that novel E. coli derived VLP vaccines displaying the influ-
enza HA globular domain (gH1) induced IFN-γ -producing gH1-specific T-cells characteristic of a potent Th1 
response30. This response was found to be dependent on ssRNA, a TLR7 agonist, contained within the VLP 
and the Th1 polarized response persisted in the presence of Th2 polarizing adjuvants such as alum. In addi-
tion this preclinical work revealed that the vaccine was able to induce humoral responses comparable to com-
mercial egg-produced vaccines. A Phase I clinical trial showed that humoral responses could also be elicited 
in humans with the vaccine achieving the primary endpoint of 60% seroconversion22. In the current work we 
demonstrate that, in addition to the induction of antibody responses, the E. coli derived VLP vaccine gH1-Qbeta 
elicits gH1-specific T-cell proliferation and production of the T helper 1 cytokine IFN-γ. These responses were 
not observed in a cohort of individuals vaccinated with the TIV vaccine, although it should be noted that this TIV 
cohort is smaller and studied separately as part of an independent clinical study. Whether the T-cell responses 
elicited by our VLP vaccine are equivalent to the protective pre-existing responses reported in the studies of 
Wilkinson et al.2 and Sridhar et al.3 remains unknown. To date a correlation between vaccine-induced T-cell 
responses and protection against influenza infection has not been demonstrated. To answer this question, further 
clinical studies are needed.
The T-cell responses described in the studies above are focused on the measurement of a single effector func-
tion, namely IFN-γ production by T-cells. By expanding the number of cytokines measured we have aimed to 
reveal a larger fraction of the antigen-specific response. Measuring a greater proportion of the types of cytokine 
responses gives information on how the quality of responses changes following vaccination. Notably it reveals the 
difficulty in changing pre-existing responses to an antigen with vaccination. In addition, it provides information 
Figure 5. Vaccination with gH1-Qbeta polarizes the quality of the gH1-specific T-cell response in some 
individuals. Shown are CD4+ proliferation and cytokine responses from cultures of PBMCs stimulated with 
a peptide pool covering the gH1 antigen sequence. PBMCs were collected both before (Pre) and 21 days after 
administration of the vaccine (Post 1). Data is from individual subjects who received either non-adjuvanted 
(Subject #2) or adjuvanted gH1-Qbeta (Subject #1, #3 and #4). FACS histogram plots are representative of one 
of three replicates and percentages of proliferating CD4+ T-cells in the gate region are indicated. Labels “Pre”, 
“Post1” and “Post2”, refer to Day 0, Day 21 and Day 42 post primary vaccination respectively.
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Figure 6. DDX17 gene expression is downregulated post vaccination with gH1-Qbeta and WGCNA/BTM 
analysis reveals clusters of genes associated with downregulation of DDX17 and upregulation of HAI and CD4 
T-cell proliferative responses. (A) Volcano plot comparing mRNA microarray data in whole blood samples from 
subjects at the pre-vaccination timepoint and at 21 days after administration of vaccine [top plots; Pre vs Post 
1] and comparing pre-vaccination to 42 days after administration of the vaccine [bottom plots; Pre vs Post 2]. 
Subjects vaccinated with adjuvanted (left column plots) and non-adjuvanted (right column plots) gH1-Qbeta 
are depicted as labelled. (B) Normalized DDX17 mRNA levels from microarray analysis of whole blood from 
subjects vaccinated with adjuvanted or non-adjuvanted gH1-Qbeta at pre-vaccination and 21 days following 
the first (Post 1) and second (Post 2) vaccination. Horizontal bars represent the median value. Friedman 
test. ****P < 0.0001; ***P < 0.001; *P < 0.05 by Dunn’s test. ns, not significant. (C) PBMCs from the cohort 
vaccinated with non-adjuvanted gH1-Qbeta were analysed by flow cytometry for DDX17 protein expression 
in a number of identified immune cell populations. Horizontal bars represent the median value. Wilcoxon test. 
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not just about desirable responses, in this case the production of the Th1 cytokine IFN-γ, but also about unde-
sirable responses. An example of such a response is the production of IL-10, which has been associated with 
reduced protection against influenza infection31. Notably we observed that both the TIV and gH1-Qb vaccines 
resulted in increased production of IL-10 when PBMCs from vaccinated individuals were cultured ex vivo. The 
ability of the gH1-Qbeta VLP vaccine to influence the quality of the cytokine response was further emphasized 
in specific individuals whose pre-existing influenza responses were characterized by a higher level of the Th2 
cytokines IL-5 and IL-13 over the Th1 cytokine IFN-γ. Following vaccination, in addition to an increasing the 
magnitude of the response, the quality of the cytokine response in these individuals trended towards a more Th1 
biased response characterized by the production of IFN-γ. An important caveat that should be highlighted when 
drawing conclusions from the studies presented here, is that although the cytokines measured are characteristic of 
polarized T cells, the possibility exists that since the PBMCs were cultivated for eight days, the cytokines initially 
produced by activated T cells could also induce cytokine production by other lymphocyte subsets. To confirm 
the cellular source of the cytokines, further clinical studies are needed using alternative techniques such as intra-
cellular cytokine flow cytometry. Blood transcript gene analysis from vaccinated subjects identified DDX17 as a 
significantly down regulated gene following vaccination with gH1-Qbeta. DDX17 is an RNA helicase involved in 
transcription and splicing. It is required by H1N1 polymerase for viral replication, therefore making this molecule 
an interesting candidate for further investigation either as a biomarker or drug target32. WGCNA analysis iden-
tified multiple gene clusters that correlated with HAI titer. One specific cluster was shown, by BTM analysis33, to 
be enriched in genes from the CORO1A-DEF6 network and correlated with HAI titer as well as the IFN-γ T-cell 
response and DDX17 expression. Coronin1A is the predominant regulator of the actin cytoskeleton in lympho-
cytes and its deficiency in humans is associated with susceptibility to infection34. DEF6 is a regulatory protein 
that modulates interferon regulatory factor 4 (IRF4) and has been shown in mice to control the ability of IRF 4 to 
regulate IL-21 B-cell responsiveness35. Further studies are required to explore the involvement of this network in 
the vaccine response.
Overall, this study showed that both non-adjuvanted and adjuvanted formulations of the gH1-Qbeta vaccine 
induced influenza-specific CD4+ and CD8+ T-cell responses and influenza-specific induction of a number of 
cytokines including anti-viral IFN-γ. Transcriptome analysis revealed gene signatures that correlate with the 
vaccine response. Further studies including a planned human challenge study with the gH1-Qbeta VLP vaccine 
will reveal any protective capability against influenza infection as well as the role of T-cell responses in protection 
and allow validation of the gene signatures identified here.
Methods
Study Design. A cohort of ten healthy volunteers aged between 21 and 56 years of age received the 
Trivalent Influenza Vaccine (TIV) (Approval #CIRB2010/720/E). The vaccine contained 15 µg HA from an A/
California/7/2009 (H1N1)pdm09-like virus, an A/Perth/16/2009 (H3N2)-like virus and a B/Brisbane/60/2008-
like virus. All volunteers received two doses of the vaccine, intramuscularly, 21 days apart.
In a separate study (Approval #CIRB2012/906/E) 84 healthy volunteers aged between 21 and 64 years 
of age received two doses of gH1-Qbeta virus-like particle pandemic influenza A (H1N1) 2009 vaccine 
(HSA CTC1300092). More details of this clinical study are reported in Low et al. 200922. Briefly this was a 
double-blinded, 1:1 randomized Phase 1 healthy volunteer study conducted at two sites in Singapore. All par-
ticipants received two intramuscular injections of 100 µg vaccine (42 µg HA) per dose, 21 days apart, either 
non-adjuvanted or adjuvanted with 2% alhydrogel, in a total volume of 500 µl per injection.
In the TIV study, subjects were excluded if they had received any previous vaccine that contained influenza 
A/California 2009 while in the gH1-Qbeta study any receipt of a seasonal influenza vaccination was an exclusion 
criteria. In addition, subjects with HAI titers >1:40 at screening were excluded.
Study approval was obtained from the Singapore Health Sciences Authority (HSA) and the Centralized 
Institutional Review Board (CIRB Ref: 2010/720/E and 2012/906/E) and the study was performed in agreement 
with the International Conference on Harmonisation guidelines on Good Clinical Practices, laws and regulatory 
requirements in Singapore. A written informed consent was obtained from each subject prior to screening.
HAI and Microneutralization (MN) assays. Serum samples from the TIV cohort were analyzed using 
standard, non-validated HAI and MN assays. For the gH1-Qbeta study validated HAI assays were performed by 
Southern Research Institute (Birmingham, AL).
Antigen specific T-cell proliferation assay. Frozen/thawed PBMC were labelled with 1 μM CFSE and 
co-cultured in complete culture medium with either overlapping peptide pools (15-mers, with a 4-aa lag, 1 μg/
ml per peptide) or the vaccine Fluarix (1 μg/ml) (105 cells per well). At day 8, cells were stained with anti-CD3Al-
exaFluor700® (UCHT1; Becton Dickinson), anti-CD8APC-Cy7 (SK1; Becton Dickinson), anti-CD4PE-Cy7 
(RPA-T4; BioLegend), anti-CD45Pacific Orange (HI30; Invitrogen), anti-CD19APC (HIB19; BioLegend) and 
7AAD viability staining solution (eBiosciences), and analysed by flow cytometry using a LSR Fortessa (BD). For 
the TIV cohort, cells were also stained with anti-PD1PE (EH12.2H7; BiolLegend), anti-ICOSPE-Cy7 (C398.4A; 
**P < 0.01; *P < 0.05; ns, not significant. (D) WGCNA analysis clustered genes with similar expression patterns 
into modules with randomly assigned colors. Each module was tested for correlation to traits of interest. 
Pearson correlation coefficients are stated in each box, with p values in brackets. Labels “Pre”, “Post1” and 
“Post2”, refer to Day 0, Day 21 and Day 42 post primary vaccination respectively.
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BioLegend) and anti-CXCR5A647 (RF8B2; Becton Dickinson). Cytokine measurements with bead-based cytokine 
multiplex analysis (Luminex) were performed at day 8. More detailed method in supplementary material.
Flow cytometry analysis of PBMCs. PBMCs were incubated with LIVE/DEAD® Fixable Aqua stain 
(ThermoFisher Scientific) followed by anti-BDCA-1 APC/Cy7 (L161; BioLegend). anti-BDCA2 PE (AC144; 
Miltenyi Biotec), anti-CD3 BUV395 (UCHT1; Becton Dickinson), anti-CD4 BUV737 (SK3; Becton Dickinson), 
anti-CD8 PE/Cy7 (53–6.7; Becton Dickinson), anti-CD11c BV421 (B-ly6; Becton Dickinson), anti-CD14 
BV711 (MΦP9; Becton Dickinson), anti-CD16 PE/Cy5 (3G8; BioLegend), anti-CD19 BV786 (SJ25C1; Becton 
Dickinson), anti-CD56 PE/CF594 (B159; Becton Dickinson) and anti-HLA-DR APC (L243; Becton Dickinson). 
Cells were fixed and permeabilised using Foxp3/Transcription Factor Staining Buffer set (eBioscience) and 
DDX17 detected in a two step process using rabbit anti-DDX17 primary (EPR13807[B]; Abcam) and by poly-
clonal secondary donkey anti-rabbit DyLight®488 (Abcam). Cells were analysed by flow cytometry using a LSRII 
analyser (BD Biosciences). Representative gating for DDX17 can be seen in Supplementary Fig. S13.
For T-cell differentiation, PBMCs were stained with LIVE/DEAD® Fixable Near-IR stain (ThermoFisher 
Scientific) followed by anti-CD3 BUV395 (UCHT1; Becton Dickinson), anti-CD25 BUV737 (2A3;Becton 
Dickinson), anti-CD8 BV650 (RPA-T8; Becton Dickinson), anti-CD4 PE (RPA-T4; Becton Dickinson), 
anti-CD45 RA ECD (2H4LDH11LDB9; Beckman Coulter) and anti-CCR7 PE-Cy7 (3D12; Becton Dickinson). 
Intracellular staining was performed for anti-FoxP3 ef450 (PCH101; eBioscience) and anti-DDX17 (as described 
above).
Microarray analysis. RNA was extracted from whole blood collected in PAXgene® Blood RNA tubes (BD 
Biosciences) using the Rneasy Mini Kit (Qiagen). RNA was amplified using TotalPrep-96 RNA Amplification 
Kit (Applied Biosystems) and hybridised to an Illumina Sentrix BeadChip Array HumanHT-12_v4_BeadChip. 
The BeadChip was scanned on a BeadArray Reader (Illumina) and analysed using BeadScan Software V2011.1 
(Illumina). Expression data was normalized and processed with the Bioconductor lumi R package. Weighted cor-
relation network analysis was carried out in the WGCNA R package with 4223 genes, after genes with low mean 
expression and low standard deviation of expression were filtered. BTM module enrichment tests, using modules 
previously described33 were conducted in R using Fisher’s exact tests with Bonferroni adjustment.
Data Availability
All the data that generated, analysed and used to support the findings of this study are available from the corre-
sponding author upon request.
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